Wellington Management Group LLP bought a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,583,154 shares of the company's stock, valued at approximately $25,632,000. Wellington Management Group LLP owned approximately 2.95% of Upstream Bio at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in UPB. BNP Paribas Financial Markets bought a new position in Upstream Bio during the 4th quarter valued at $25,000. US Bancorp DE purchased a new stake in shares of Upstream Bio in the fourth quarter valued at about $27,000. Legal & General Group Plc bought a new position in shares of Upstream Bio during the fourth quarter valued at about $28,000. Summit Investment Advisors Inc. purchased a new position in Upstream Bio during the fourth quarter worth about $30,000. Finally, Tower Research Capital LLC TRC bought a new stake in Upstream Bio in the 4th quarter worth about $47,000.
Upstream Bio Stock Up 0.2%
UPB stock traded up $0.02 during midday trading on Wednesday, hitting $10.86. The company's stock had a trading volume of 213,207 shares, compared to its average volume of 334,606. The stock's 50-day moving average price is $8.41 and its 200 day moving average price is $11.56. Upstream Bio, Inc. has a 1 year low of $5.14 and a 1 year high of $29.46.
Upstream Bio (NASDAQ:UPB - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The firm had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.71 million. Analysts expect that Upstream Bio, Inc. will post -4.3 EPS for the current year.
Upstream Bio Company Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Recommended Stories
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
